van Dalem J, Driessen JHM, Burden AM, et al. - This study was carried out to explore the relationship between the risk of nonalcoholic fatty liver disease (NAFLD) and the use of thiazolidinediones and glucagon-like peptide-1 (GLP-1) receptor agonists compared with the use of sulfonylureas and insulins. The incidence of hepatocellular carcinoma (HCC) in users of thiazolidinediones (TZDs) and GLP-1 receptor agonists was calculated. Researchers performed a population-based cohort study using primary care data from the Clinical Practice Research Datalink database (2007-2018). They enrolled all individuals aged ≥ 18 with a prescription of an oral glucose-lowering agent or GLP-1 receptor agonist. This study demonstrates the use of TZDs for selected patients at risk of NAFLD but does not support previous findings regarding the beneficial effect of GLP-1 receptor agonists. In several subgroups, the low number of events may affect the generalizability of the current findings.